Patents by Inventor Richard Straube

Richard Straube has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell Lymphoma
    Publication number: 20230024050
    Abstract: A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm2 and increases to a maximum dose of about 12 J/cm2.
    Type: Application
    Filed: July 8, 2022
    Publication date: January 26, 2023
    Inventors: Oreola Donini, Richard Straube, Christopher Schaber
  • Peptides having binding affinity to an antibody which recognizes an epitope on an ?1 loop 2 or ?2 loop 1 of an adrenoreceptor
    Patent number: 9574017
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: February 21, 2017
    Assignees: MDC Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN ALPHA1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR
    Publication number: 20130302292
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Application
    Filed: April 26, 2013
    Publication date: November 14, 2013
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • Peptides having binding affinity to an antibody which recognizes an epitope on an ?1 loop 2 or ?2 loop 1 of an adrenoreceptor
    Patent number: 8455442
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: June 4, 2013
    Assignees: MDC Max-Delbruck-Centrum fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN A1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR
    Publication number: 20110104226
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 5, 2011
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube